Managing moderate-to-severe inflammatory bowel disease requires precise sequencing of advanced medical therapies. Clinicians frequently evaluate infliximab and tofacitinib in ulcerative colitis to achieve long-term mucosal healing and symptom control. Although both agents offer robust efficacy, direct comparative real-world evidence remains scarce, particularly regarding prior biologic exposure. A multicenter cohort study recently evaluated how prior treatment history influences clinical outcomes. Consequently, these new findings provide essential real-world guidance for gastroenterologists seeking to optimize individualized therapy selection across distinct patient groups.

Real-World Evidence on Tofacitinib in Ulcerative Colitis

Real-world clinical studies provide indispensable insight into drug performance outside the strict boundaries of randomized clinical trials. Specifically, patients encountered in routine gastroenterology practice present with greater comorbidities, varied disease durations, and diverse medication histories. In this multicenter Japanese study, researchers analyzed adult patients with ulcerative colitis who initiated either infliximab or tofacitinib. To minimize historical selection bias, investigators restricted the primary comparative analysis to patients initiating therapy after May 2018, when both agents were concurrently available.

Furthermore, the investigators categorized patients into two distinct analytical groups: advanced therapy-naive and advanced therapy-exposed cohorts. Because baseline differences could skew comparative results, the researchers employed overlap weighting methodology to balance clinical characteristics across cohorts. This advanced statistical approach ensured robust balance while preserving sample size. The primary endpoint evaluated corticosteroid-free clinical remission at week 52. In addition, the researchers assessed interim clinical responses at week 14 alongside three-year treatment persistence. Therefore, this rigorous real-world framework delivers valuable comparative effectiveness data directly applicable to daily clinical decision-making.

Induction Outcomes and Early Symptom Control

Rapid symptom resolution represents a crucial goal during the acute management of ulcerative colitis flares. Clinicians rely heavily on early response benchmarks to determine whether an induction regimen warrants continuation. Interestingly, this comparative analysis demonstrated that week 14 clinical remission rates did not differ significantly between infliximab and tofacitinib. This equivalence remained consistent across both the therapy-naive cohort and the therapy-exposed cohort.

Consequently, both therapeutic agents provide dependable early control regardless of a patient's prior biologic treatment history. Infliximab binds soluble and membrane-bound tumor necrosis factor with high affinity, thereby rapidly dampening mucosal inflammation. Similarly, tofacitinib rapidly inhibits downstream cytokine signaling by blocking Janus kinase pathways. Because both medications achieve prompt pharmacodynamic suppression, clinicians can expect comparable induction success during early follow-up. However, early symptom control does not always guarantee sustained disease control over the subsequent months. Therefore, clinicians must look beyond short-term induction markers and focus on intermediate- and long-term durability metrics when selecting therapeutic agents. Additionally, regular objective monitoring through fecal calprotectin and endoscopic evaluations ensures that early clinical improvements truly reflect transmural disease quiescence.

Week 52 Remission in Advanced Therapy-Naive Cohorts

Long-term therapeutic efficacy becomes evident as patients transition from initial induction to maintenance regimens. At week 52, the primary outcome of corticosteroid-free clinical remission revealed compelling patterns among advanced therapy-naive patients. Specifically, patients receiving tofacitinib achieved a 64.5% corticosteroid-free remission rate compared to 43.9% among those receiving infliximab. Although this difference favored tofacitinib with an odds ratio of 2.32, it did not reach formal statistical significance.

Nevertheless, this numerical advantage highlights the potent therapeutic capabilities of oral small molecules as frontline advanced therapies. Traditionally, clinicians reserved Janus kinase inhibitors exclusively for patients who previously failed anti-tumor necrosis factor therapies. However, these real-world data challenge that restrictive treatment paradigm. Because tofacitinib demonstrates substantial maintenance efficacy in biologic-naive individuals, it represents an appealing first-line alternative to traditional biological infusions. Moreover, multiple imputation sensitivity analyses confirmed consistent results across missing data models. Thus, clinicians may confidently discuss tofacitinib as a viable frontline choice during collaborative treatment discussions with treatment-naive patients. Furthermore, avoiding systemic intravenous infusions can greatly enhance patient treatment adherence and overall lifestyle flexibility.

Superior Maintenance Remission in Advanced Therapy-Exposed Patients

Patients who fail prior advanced therapies represent a particularly challenging population in inflammatory bowel disease clinics. In this study, the advanced therapy-exposed cohort revealed statistically significant advantages favoring tofacitinib. Specifically, 38.8% of therapy-exposed patients treated with tofacitinib achieved corticosteroid-free clinical remission at week 52, compared to only 19.0% treated with infliximab. This marked difference yielded an odds ratio of 2.71 with a nominal p-value of 0.034.

Consequently, tofacitinib demonstrated clear clinical superiority over infliximab in patients who had already failed previous biological agents. Biologic exposure often induces refractory inflammatory pathways that bypass standard cytokine neutralization. Because tofacitinib provides broad intracellular cytokine inhibition, it effectively overcomes alternative inflammatory cascades that drive biologic resistance. Additionally, small molecules do not trigger immunogenic anti-drug antibodies, which frequently diminish biologic efficacy over time. Therefore, these real-world findings strongly endorse positioning tofacitinib as an effective second-line therapy after anti-TNF failure. Gastroenterologists managing refractory ulcerative colitis can leverage this evidence to guide decisive therapy transitions. Moreover, timely switching to an oral small molecule prevents unnecessary steroid exposure and reduces the cumulative risk of disease-related hospitalizations.

Three-Year Persistence and Long-Term Treatment Durability

Long-term treatment persistence serves as an essential composite marker of therapeutic durability, encompassing real-world efficacy, safety, and patient adherence. In this study, overall three-year persistence rates showed no statistically significant differences between infliximab and tofacitinib across both cohorts. However, the data revealed a notable numerical divergence among advanced therapy-naive patients over the extended three-year follow-up.

Specifically, 61.5% of therapy-naive patients maintained tofacitinib therapy at three years, compared to 39.2% of those receiving infliximab. This divergence yielded a favorable hazard ratio of 0.64 for tofacitinib discontinuation. Although the study could not confirm statistical significance due to sample size constraints, clinically meaningful differences remain plausible. Infliximab therapy often faces long-term attrition caused by immunogenicity and neutralizing antibody development. Conversely, tofacitinib maintains stable pharmacokinetic action without antibody-mediated clearance. Furthermore, convenient twice-daily oral dosing provides logistical advantages over regular intravenous clinic infusions. Consequently, tofacitinib represents a durable long-term maintenance strategy that promotes sustained disease control and minimizes therapy switches. Thus, clinicians evaluating long-term care plans should weigh these persistence trends when counseling patients regarding durability.

How does prior biologic exposure affect response to tofacitinib in ulcerative colitis?

Prior exposure to biologics often reduces response rates across subsequent therapies in inflammatory bowel disease. However, evidence shows that tofacitinib retains substantial clinical effectiveness in advanced therapy-exposed patients. Because tofacitinib targets intracellular Janus kinase signaling pathways rather than extracellular cytokines, it bypasses anti-drug antibodies and receptor-specific resistance. Consequently, clinicians frequently select this oral small molecule as a highly dependable second-line or salvage therapy for patients who fail anti-tumor necrosis factor agents.

What are the primary safety considerations when initiating tofacitinib in clinical practice?

Clinicians must carefully evaluate patient cardiovascular risk factors, thromboembolic history, and baseline infection vulnerability before initiating tofacitinib. Because Janus kinase inhibition suppresses multiple cytokine pathways, patients carry an elevated risk of herpes zoster reactivation and opportunistic infections. Therefore, proactive recombinant zoster vaccination and routine screening for latent tuberculosis remain vital steps. Furthermore, clinicians must periodically monitor lipid profiles, complete blood counts, and hepatic enzymes throughout therapy to maintain safe long-term disease management.

How does treatment persistence compare between infliximab and tofacitinib over three years?

Real-world data indicate that long-term treatment persistence does not significantly differ between infliximab and tofacitinib over three years overall. Nevertheless, tofacitinib demonstrates a notable numerical trend toward higher persistence in advanced therapy-naive cohorts. Because tofacitinib is a small molecule, it carries no immunogenicity risk, eliminating secondary loss of response driven by neutralizing anti-drug antibodies. Consequently, convenient oral administration and sustained pharmacological stability may contribute to improved therapy continuation for select patient populations.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment recommendations. Refer to the latest local and national guidelines for clinical practice.

References

1. Mizuta N et al. Comparative effectiveness of infliximab and tofacitinib in advanced therapy-naive and -exposed patients with ulcerative colitis: a multicenter real-world study. Inflamm Bowel Dis. 2026 Nov 10. doi: undefined. PMID: 43007333.


2. Narula N, Wong ECL, Colombel JF, et al. Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study. Dig Dis Sci. 2023;68(8):3396-3404.


3. Buisson A, Serrero M, Altwegg R, et al. Real-World Comparison of the Effectiveness of Tofacitinib and Ustekinumab in Patients With Ulcerative Colitis: The TORUS Study. Clin Gastroenterol Hepatol. 2026;24(4):1141-1150.